Sign in
Not yet taking people in NetherlandsPhase 2

Tests a drug added to brain stimulation for depression

Tests D-cycloserine added to magnetic brain stimulation in adults with depression.

Key facts

Who runs it
Universiteit Maastricht
Where
Maastricht, NetherlandsSee the 2 sites
Registry title
TMSxDCS: Medicinal improvement of brain stimulation for depression.
Status
Not yet recruiting
Phase
Phase 2
People taking part
48 people, planned
Started
17 Aug 2026
Expected to end
12 Dec 2027
Type of study
Interventional
Record updated
21 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with major depression that has not improved enough with at least 2 antidepressant medicines. It tests brain stimulation (TMS) together with the medicine D-cycloserine.

Age
18 to 65 years (the record also lists a maximum age of 64 years)
Sex
All sexes can join.
Disease stage
Major depressive disorder, a current moderate to severe episode (MADRS score above 20), treatment resistant.
Earlier treatment
Has tried at least 2 types of antidepressant medicine without enough effect. No change in antidepressant treatment (medicine or psychotherapy) in the 4 weeks before joining.

Main reasons for not taking part

  • Pregnancy at joining or during the study
  • Metal implants or a cochlear implant near the head
  • Bipolar disorder, psychosis or schizophrenia in the past, or another main psychiatric diagnosis
  • Kidney insufficiency in the past or current substance abuse disorder
  • Use of olanzapine, clozapine, ethionamide or isoniazid, or regular scheduled use of benzodiazepines

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • A primary diagnosis of MDD, with a current moderate to severe depressive episode (score of >20 on the MADRS)
  • Age between 18-65 years old
  • A diagnosis of moderate to severe measures of treatment resistant depression (TRD) and have tried at least 2 types of antidepressant medication without sufficient result

Who cannot take part

  • Any change in antidepressant treatment (medication, psychotherapy) 4 weeks prior to enrollment
  • Has a cochlear implant
  • Metal implants near (<10 cm away from coil) the head including: - Aneurysm clips / coils - Any medical implant containing metal near the head - Metal stents in the brain - Shrapnel or bullet fragments - Implanted vagus nerve or deep brain stimulators, Electrodes for monitoring brain activity
  • Current scheduled use of benzodiazepines (as needed use is permitted, except for the day prior to treatment)
  • Current use of any of the following medications: Olanzapine, clozapine, ethionamide, isoniazid
  • Primary psychiatric diagnosis other than MDD
  • A history of bipolar disorder
  • A history of psychosis
  • A history of schizophrenia
  • A history of renal insufficiency
  • Current substance abuse disorder
  • Pregnancy upon inclusion or during the study period, though women with childbearing potential will be included into the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Netherlands

  • Brain ModulationMaastricht, NetherlandsNot yet recruiting
  • Universiteit MaastrichtMaastricht, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

The primary objective of this study is to investigate the antidepressive effect of augmenting a single day of accelerated transcranial magnetic stimulation (TMS) with D-cycloserine (DCS).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
TMSxDCS: Pharmacologically augmenting transcranial magnetic stimulation for depression
Plain-language title
Tests a drug added to brain stimulation for depressionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2025-521166-95-00, who can take part
Record updated
21 September 2026